Medpace Holdings Inc vs TJX Companies Inc — how do they compare? Medpace Holdings Inc trades at $531.27 (market cap $15.08B), while TJX Companies Inc trades at $154.8 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 11.4× Medpace Holdings Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TJX | |
|---|---|---|
Market Cap | $15.08B | $172.00B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $168.41 |
52-Week Low | $308.88 | $124.53 |
Enterprise Value | $14.55B | $180.60B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
TJX trades at $155.47, up 0.7% on the day, with a bullish technical signal and strong fundamental performance. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Revenue growth is robust, reaching $56.36 billion in 2025, with a net income margin of 9.4%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $181.80, suggesting significant upside potential from current levels.
The outlook for TJX remains favorable, driven by sustained earnings beats, expanding margins, and strategic international growth. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. With strong cash flow generation supporting dividends and buybacks, TJX presents a compelling growth story, though valuation metrics like a P/E of 30.05 warrant monitoring for overextension.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →